Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 16 2024 - 4:05PM
OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on
patients treated by ear, nose and throat (ENT) and allergy
specialists, today announced that the company has granted a
non-qualified stock option awards to purchase an aggregate of
185,000 shares of its common stock to eight new employees as an
inducement material for accepting employment with OptiNose. The
stock option awards were granted outside of the OptiNose, Inc. 2010
Stock Incentive Plan in accordance with Nasdaq Listing Rule
5635(c)(4).
The stock options were granted to the new
employees on their respective hire dates (October 7, 2024, and
October 14, 2024) with an exercise price equal to the closing price
of the company’s common stock as reported by Nasdaq on the grant
date ($0.71 per share, on both dates).
The stock options have a 10-year term and vest
over four years, with one-fourth of the shares underlying the stock
option vesting on the first anniversary of the grant date and the
remainder vesting in thirty-six equal monthly installments
thereafter. Vesting of the stock options is subject to continued
service with the company through the applicable vesting date.
About OptinoseOptinose is a specialty
pharmaceutical company focused on serving the needs of patients
cared for by ear, nose and throat (ENT) and allergy specialists. To
learn more, please visit www.optinose.com or follow us on
Twitter and LinkedIn.
Optinose Investor ContactJonathan
Neelyjonathan.neely@optinose.com267.521.0531
OptiNose (NASDAQ:OPTN)
Historical Stock Chart
From Nov 2024 to Dec 2024
OptiNose (NASDAQ:OPTN)
Historical Stock Chart
From Dec 2023 to Dec 2024